Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: KRAS Gene Mutation Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Solid Tumor
Interventions
BBP-398 with nivolumab
Drug
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors (Phase 1), RAS Mutation
Interventions
AN9025 oral capsule
Drug
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions
LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced NSCLC, Metastatic Lung Cancer
Interventions
Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
Drug · Combination Product
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
84
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced May 22, 2026, 1:39 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer
Interventions
BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Chandler, Arizona • Goodyear, Arizona • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Panitumumab, Trametinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions
Divarasib, Sotorasib, Adagrasib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions
JDQ443
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions
JDQ443, TNO155, tislelizumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
Drug · Biological
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
185
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Interventions
HBI-2438
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Encinitas, California • Glendale, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation; SOS1
Interventions
BI 1701963, Trametinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
daraxonrasib, docetaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
34
States / cities
Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions
Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
44
States / cities
Anchorage, Alaska • Goodyear, Arizona • Greenbrae, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, KRAS Mutation-Related Tumors
Interventions
NEROFE, Doxorubicin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 22, 2026, 1:39 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ERAS-007, Encorafenib, Cetuximab, Palbociclib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
KRAS G12D Mutation, Advanced Solid Cancer
Interventions
ARV-806
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 22, 2026, 1:39 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MEK162, Erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced May 22, 2026, 1:39 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Everolimus, Neratinib, Palbociclib, Trametinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 1:39 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Imprime PGG
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Minneapolis, Minnesota • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced May 22, 2026, 1:39 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
16
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 1:39 AM EDT